F R I DAY, A P R I L 1 0, 2 0 2 6
Walter E. Washington Convention Center
Room 102 AB
Registration and Lunch: 11:30 a.m.
Program: 12:00 p.m.–1:00 p.m.
This program is non-CME.
Brandon
Ayres, MD
Ken
Beckman, MD
Maanasa
Indaram, MD
Ma•
Jensen
M O D E R AT O R FAC U LT Y
Introducing Epioxa, the first and only
FDA approved epithelium-on oxygen
enriched corneal cross-linking treatment
Sponsored by
R E G I ST E R TO DAY !
Meetings.EyeWorld.org/Glaukos
INDICATIONS AND USAGE
EPIOXA™ HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5'-phosphate
ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking
for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the
O2n™ System and the Boost Goggles®.
IMPORTANT SAFETY INFORMATION
Contraindications
EPIOXA™ HD and EPIOXA™ are contraindicated in patients with known hypersensitivity to benzalkonium
chloride (BAC) or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is
contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.
Warnings and Precautions
Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the
potential for reactivation of herpes keratitis.
Adverse Reactions
The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5%
to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased
lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior
chamber flare.
Dosage and Administration
EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use.
EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes aŽer use.
EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only.
Refer to the O2n System Operator's Manual and Boost Goggles User Guide for device instructions.
Please see full Prescribing Information for EPIOXA HD and EPIOXA at www.Epioxa.com.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also call Glaukos at 1-888-404-1644.
Glaukos is a registered trademark of Glaukos Corporation. All rights reserved. © 2026 NPM-US-0036
